News from all angles
(MedPage Today) -- The first-in-class RAS inhibitor daraxonrasib (Rasonque) in combination with chemotherapy showed promise as a first-line treatment for patients with metastatic pancreatic adenocarc…
Redirecting to MedPage Today in 3 seconds...
Share this story with your network